All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Addition of venetoclax to hyper-CVAD-nelarabine-pegAsp for T-ALL/LBL: 2-year follow-up from the phase II trial
Bookmark this article
|
Venetoclax is a BCL-2 inhibitor that demonstrated activity in preclinical and early-phase studies in patients with ETP-ALL/LBL. A phase II trial (NCT00501826) evaluated the outcomes of hyper-CVAD-nelarabine-pegAsp (original cohort) in adults with untreated T-ALL/LBL. In the latest protocol iteration of this trial, venetoclax was added to the induction/consolidation regimen (venetoclax cohort). The long-term results published in Leukemia by Ravandi et al.1 assessed the outcomes of adding venetoclax to the original cohort in 145 patients. The primary endpoint was the improvement in 2-year PFS and OS with venetoclax. |
| Key learnings |
| With a median follow-up of 62.4 months, 5-year PFS, DoR, and OS were 63.7%, 72.0%, and 66.2%, respectively, in the whole cohort. |
| The venetoclax cohort demonstrated higher 2-year PFS (87.9% vs 64.1%; p = 0.03) and DoR (93.6% vs 69.2%; p = 0.005) vs the original cohort. |
| The venetoclax cohort showed improved 2-year OS vs the original cohort (87.8% vs 73.9; p = 0.16). |
| Febrile neutropenia was the most common serious AE (60%); neurotoxicity and thromboembolic events were reported at lower rates (7.6% and 5.5%, respectively). |
| Overall, the promising efficacy and safety data suggest that the addition of venetoclax to hyper-CVAD-nelarabine-pegAsp could be a viable treatment option for adult patients with T-ALL/LBL. |
Abbreviations: DoR, duration of response; ETP, early T-cell precursor; hyperCVAD, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; LBL, lymphoblastic lymphoma; pegAsp, pegylated asparaginase; PFS, progression-free survival; OS, overall survival; T-ALL, T-cell acute lymphoblastic leukemia.
- Ravandi F, Senapati J, Jain N, et al. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. 2024. Online ahead of print. DOI: 10.3324/haematol.2024.285837
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox